Company intelligence / Profile preview

Tenpoint Therapeutics

London, United Kingdomtenpointtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Tenpoint's lead product BRIMOCHOL PF has completed two Phase 3 pivotal trials (BRIO-I and BRIO-II) for presbyopia treatment. The company submitted an NDA to the FDA on April 8, 2025, with plans for commercial launch in the first half of 2026. The trials demonstrated statistically significant improvements in near vision with 3-lines or greater improvement in binocular uncorrected near visual acuity over 8 hours without loss of distance vision.

Therapeutic areas: Ophthalmology
Modalities: Small moleculescell-based therapiesin vivo reprogramming
Industry: Biotech

Drug pipeline

3 assets

BRIMOCHOL

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Merged with Visus Therapeutics Inc. in December 2024

Beyond the preview

Go deeper on Tenpoint Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenpoint Therapeutics.

Explore the full profile